Innate Pharma Net Asset Quality Index
Innate Pharma net asset quality index. Innate Pharma (IPH) has a Net Asset Quality Index of -34.6% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €62.72 Million minus total liabilities of €84.42 Million yields net assets of €-21.70 Million. A higher index indicates a stronger, lower-leverage balance sheet. See what is Innate Pharma's book value for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Innate Pharma (2003–2025)
Net asset quality index of Innate Pharma from 2003 to 2025. This chart shows how Innate Pharma's Net Asset Quality Index has evolved across 23 annual periods from 2003 to 2025. As of December 2025, the index stands at -34.6%, representing net assets of €-21.70 Million against total assets of €62.72 Million EUR. Check Innate Pharma strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Innate Pharma Net Asset Quality Index by Year (2003–2025)
Innate Pharma net asset quality index by year from 2003 to 2025. The table below presents the year-by-year Net Asset Quality Index for Innate Pharma from 2003 to 2025, covering 23 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see IPH market cap overview.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -34.6% | €-21.70 Million | €62.72 Million | €84.42 Million | ▼ -42.6 pp |
| 2024 | 8.0% | €8.83 Million | €111.06 Million | €102.22 Million | ▼ -20.2 pp |
| 2023 | 28.2% | €51.90 Million | €184.19 Million | €132.29 Million | ▲ +2.1 pp |
| 2022 | 26.1% | €54.15 Million | €207.86 Million | €153.71 Million | ▼ -14.1 pp |
| 2021 | 40.2% | €107.44 Million | €267.50 Million | €160.06 Million | ▼ -10.6 pp |
| 2020 | 50.7% | €155.97 Million | €307.42 Million | €151.45 Million | ▼ -3.4 pp |
| 2019 | 54.2% | €217.42 Million | €401.36 Million | €183.94 Million | ▲ +17.1 pp |
| 2018 | 37.1% | €167.24 Million | €451.22 Million | €283.98 Million | ▲ +3.4 pp |
| 2017 | 33.7% | €85.96 Million | €255.02 Million | €169.07 Million | ▲ +3.1 pp |
| 2016 | 30.6% | €86.17 Million | €281.58 Million | €195.41 Million | ▲ +7.0 pp |
| 2015 | 23.6% | €72.07 Million | €305.96 Million | €233.89 Million | ▼ -58.7 pp |
| 2014 | 82.3% | €74.63 Million | €90.69 Million | €16.06 Million | ▲ +10.2 pp |
| 2013 | 72.1% | €40.29 Million | €55.88 Million | €15.60 Million | ▲ +23.7 pp |
| 2012 | 48.4% | €23.36 Million | €48.30 Million | €24.93 Million | ▲ +4.1 pp |
| 2011 | 44.3% | €26.62 Million | €60.11 Million | €33.48 Million | ▼ -25.5 pp |
| 2010 | 69.8% | €33.52 Million | €48.01 Million | €14.49 Million | ▼ -3.6 pp |
| 2009 | 73.4% | €47.12 Million | €64.22 Million | €17.10 Million | ▲ +5.5 pp |
| 2008 | 67.9% | €41.34 Million | €60.86 Million | €19.52 Million | ▼ -10.6 pp |
| 2007 | 78.5% | €49.61 Million | €63.15 Million | €13.55 Million | ▼ -2.8 pp |
| 2006 | 81.4% | €56.37 Million | €69.25 Million | €12.89 Million | ▲ +0.4 pp |
| 2005 | 81.0% | €20.07 Million | €24.77 Million | €4.70 Million | ▼ -3.7 pp |
| 2004 | 84.8% | €25.01 Million | €29.51 Million | €4.50 Million | ▲ +10.6 pp |
| 2003 | 74.1% | €15.11 Million | €20.38 Million | €5.27 Million | — |